Previously , we reported that adenoviral vector-mediated transfer of the human aquaporin-1 (hAQP1) cDNA to minipig parotid glands following irradiation (IR) transiently restored salivary flow to near normal levels. This study evaluated a serotype 2, adeno-associated viral (AAV2) vector for extended correction of IR (single dose; 20 Gy)-induced, parotid salivary hypofunction in minipigs. At 16 weeks following the IR parotid salivary flow decreased by 85-90%. AAV2hAQP1 administration at week 17 transduced only duct cells and resulted in a dose-dependent increase in salivary flow to B35% of pre-IR levels (to B1 ml per 10 min) after 8 weeks (peak response). Administration of a control AAV2 vector or saline was without effect. Little change was observed in clinical chemistry and hematology values after AAV2hAQP1 delivery. Vector-treated animals generated high anti-AAV2 neutralizing antibody titers by week 4 (B1:1600) and significant elevations in salivary (B15%), but not serum, granulocyte macrophage colony-stimulating factor levels. Following vector administration, salivary [Na + ] was dramatically increased, from B10 to B55 mM (at 4 weeks) and finally to 39 mM (8 weeks). The findings demonstrate that localized delivery of AAV2hAQP1 to IR-damaged parotid glands leads to increased fluid secretion from surviving duct cells, and may be useful in providing extended relief of salivary hypofunction in previously irradiated patients.
INTRODUCTION
Oral cavity and pharyngeal (oral) cancers are fairly common, and each year in the United States there are 35 000-40 000 new cases. 1 The treatment of most patients with oral cancers includes radiation therapy, and recent data show a survival rate of B60% for patients with this type of neoplasm. 1 Salivary glands in the radiation field suffer irreversible damage leading to a marked reduction in salivary flow and, as a consequence, xerostomia, dysphagia and oral infections. 2, 3 Moreover, this irradiation (IR)-induced salivary hypofunction results in a significant diminution in quality of life for surviving oral cancer patients. 4, 5 Despite considerable effort to prevent or limit this problem (for example, see Brizel and Overgaard 6 , Vergeer et al 7 , Cotrim et al 8 , Epperly et al 9 ) many surviving patients experience significant salivary hypofunction, that is, in the Radiation Therapy Oncology Group's categories 2 and 3. 10 Currently, there is no effective treatment available for these individuals. As a result, for many years we have tried to develop a novel, gene transfer-based corrective treatment for IR-induced salivary hypofunction, 11 using the human aquaporin-1 (hAQP1) cDNA 12 encoded within a serotype 5 adenoviral vector (AdhAQP1). 13, 14 As a result of pre-clinical efficacy studies in rats and miniature pigs (minipigs), 13, 14 and extensive safety studies, 15 we received approval to conduct a phase I clinical study with AdhAQP1, treating a single parotid gland of previously irradiated patients, which is ongoing (http://www.clinicaltrials.gov/ct/show/NCT00372320?order¼).
A drawback to the strategy of using AdhAQP1 is that any beneficial results experienced by patients would be relatively short lived because of the transient nature of adenoviral vector-mediated transduction of salivary glands. 16 As a result, we have also developed a serotype 2 adeno-associated viral (AAV2) vector encoding hAQP1, AAV2hAQP1, which is capable of increasing net fluid secretion across polarized salivary epithelial cell layers in vitro. 17 AAV2 vectors mediate longterm transgene expression in the salivary glands of mice (41 year) and non-human primates (up to 6 months; longest time studied). 18, 19 In the present series of experiments, we used a single dose IR scheme (20 Gy) to reduce parotid salivary flow and test the hypothesis that AAV2hAQP1 could increase fluid secretion from irradiated parotid glands of minipigs for an extended time period. Although patients typically receive fractionated IR dosing, our previous studies in mice have shown quite similar effects of single and fractionated IR dosing on salivary flow rates. 20 Minipig parotid glands provide an excellent and readily affordable (for example, much less expensive than non-human primates) model of IR-induced salivary hypofunction in large animals (B25-30 kg). 21 Furthermore, minipig salivary duct cells, which survive IR, are readily transduced by AAV2 vectors, albeit effective gene transfer is not as long-lived as seen in other species, with peak transgene expression occurring at B8-10 weeks and returning to background levels by B32 weeks. 22 The results reported herein support our hypothesis.
RESULTS AND DISCUSSION
After a single radiation dose of 20 Gy to targeted parotid glands, there is a marked reduction in salivary flow rate (Figure 1) . At 16 weeks after IR, the average rate of saliva production from the targeted glands (n¼9) had fallen to B15% of pre-IR levels. Preliminary experiments with separate cohorts of minipigs established both the optimal time to measure vector effects (B8-10 weeks; three animals were followed for 24 weeks after IR; see Supplementary Figure 1 ), as well as the optimal dose to administer (10 11 vector particles (vp)/gland; two animals/dose; Figure 2a ). Both results were consistent with previous findings with minipig parotid glands using an AAV2 vector encoding erythropoietin. 22 At week 17, the animals shown in Figure 1 were divided into three groups (n¼3/group) and either administered the AAV2hAQP1 vector, a control vector (AAV2LacZ), both at 10 11 vp/gland, or saline (the diluent buffer used) to the IR-damaged parotid gland. Thereafter, salivary flow rates were monitored every 2 weeks for 8 weeks as shown (Figure 2b ). By the eight week, post-vector administration time point parotid salivary flow rates for animals treated with AAV2LacZ or saline buffer continued to diminish to 12 and 11%, respectively, of the pre-IR values. Conversely, in glands treated with the AAV2hAQP1 vector a steady increase in parotid salivary flow rates was seen, such that by week 8 they were on average B35% of pre-IR values, to nearly 1 ml per 10 min (Figure 2b ).
We next examined the expression of the transgenic hAQP1 in transduced glands. Initially, we used western blotting to determine the expression of hAQP1 in crude parotid membranes (Figure 3 ). At 8 weeks following treatment, membranes from minipigs Figure 1 Effect of irradiation (IR) on parotid saliva flow rate in minipigs. One parotid gland of animals (n¼9) was irradiated with 20 Gy, as described in the Materials and Methods. Parotid saliva flow rates were thereafter measured at weeks 4 and 16. Data shown are the mean ± s.d. of salivary flow rates for the targeted glands (open bars; note that for the 16 week value the s.d. is too small to be seen) and the contralateral glands (black bars). Data were analyzed using a one-way analysis of variance (F¼72.69, Po0.001), followed by the Tukey test. For the irradiated side, the values at +4 and +16 weeks are significantly different from that before IR (Po0.001, as well as different from each other, Po0.001). Similar differences exist for the values for the nonirradiated side (Po0.01), although there is no difference between the +4 and +16 week values. The parotid flow rates on the two sides are significantly different at +4 (P¼0.031) and +16 weeks (Po0.001). are too small to be seen. Data were analyzed using a one-way analysis of variance (F¼27.88, Po0.001), followed by the Tukey test. All of the parotid flow rates for the AAV2hAQP1-treated minipigs are significantly different from those of the buffer and AAV2LacZ-treated animals at weeks 4 (Po0.01 versus buffer; Po0.05 versus AAV2LacZ), 6 (Po0.001) and 8 (Po0.001). There were no significant differences in parotid flow rates between the buffer and AAV2LacZ-treated animals at every time point.
AAV2hAQP1 and radiation-induced xerostomia R Gao et al administered AAV2LacZ or saline displayed low levels of AQP1 expression in the irradiated glands (lanes 3, 4 in Figure 3 ). Conversely, membranes obtained from the non-irradiated, contralateral gland showed a modest level of AQP1 present (lane 5). These three results are consistent with the known loss of parenchymal tissue that occurs following radiation damage to salivary glands and the presence of endogenous AQP1 in salivary microvascular endothelial cells. 8, 14, 23 In parotid membranes from irradiated glands of animals treated with AAV2hAQP1 there was a high level of AQP1 protein present (lane 2), indicating significant transduction of the targeted tissue occurred. We next examined parotid tissue by immunocytochemistry to determine the cell type transduced by the AAV2hAQP1 vector. The only parotid epithelial cells exhibiting AQP1-positive staining were duct cells transduced by AAV2hAQP1 (not shown). This immunostaining pattern is consistent with the known targeting of AAV2 vectors to minipig parotid duct cells, as assayed with a vector encoding E. coli b-galactosidase. 22 As noted, similar to our previous report, 22 peak parotid salivary flow rates occurred between weeks 6-10 and declined thereafter, decreasing by B20% from week 10 to week 12 (Supplementary Figure  1) . We hypothesized that this was likely due to a cellular immune response and examined serum and saliva samples for the presence of several cytokines. Specifically, we measured the levels of granulocyte macrophage colony-stimulating factor, interleukin-2, interleukin-6, interferon g and macrophage inflammatory protein-1b in both fluids. When compared with observations following saline administration, 8 weeks after administration of 10 11 AAV2hAQP1 vp no significant changes were seen in the levels of all five cytokines measured in serum (not shown). Similar results were found for all cytokines in saliva, except for salivary granulocyte macrophage colony-stimulating factor levels, which was elevated significantly (B15%; average value 509 versus 444 pg ml À1 ), a finding consistent with our hypothesis. Clearly more study is required to understand these events. 24, 25 An enhanced cellular immune response may also have occurred when glands were transduced with 3Â10 11 vp/gland (Figure 2a) .
The levels of serum anti-AAV2 neutralizing antibodies, although unlikely related to the decreasing fluid secretion seen after 8 weeks in the transduced animals, were also measured. Saline-administered minipigs had essentially no neutralizing antibodies directed at AAV2 at either week 4 or week 8 (not shown). Conversely, animals treated with 1Â10 11 AAV2hAQP1 vp had on average a neutralizing antibody titer of B1:1600 at week 4 and 1:6400 at week 8.
To assess overall vector safety following administration of the AAV2hAQP1vector, we examined multiple clinical chemistry and hematology parameters, as we have previously done in a study conducted with the AdhAQP1 vector. 15 Vector treatment had little effect on animal general well being (see Supplementary Table 1 ). The only significant hematological change was a slight elevation in hematocrit values at week 8 after vector delivery. There were no significant alterations in serum chemistry values. Furthermore, all treated animals appeared to eat normally, gain weight and thrive.
Finally, we examined the composition of saliva obtained from the targeted parotid glands (Table 1) . Several changes were found following IR, as well as following AAV2hAQP1vector administration, particularly in electrolytes. It is notable that [Na + ] was reduced (B30%; not significant) at 16 weeks after IR and then, following hAQP1 gene transfer, there was a marked elevation in [Na + ] at both 4 and 8 weeks (4-5-fold). Total [Ca 2+ ] was dramatically reduced by IR (B50%), and remained low after gene transfer. There was also an elevation in [K + ] after IR, which returned to pre-IR levels following gene transfer. Finally, [Cl À ] in parotid saliva was reduced following vector administration. These results, with the particular exception of those for Na + , are reasonably similar to our observations 3 days following AdhAQP1-mediated gene transfer to irradiated minipig parotid glands. 14 The Na + values following gene transfer, however, are quite different and likely are a result of (i) the longer time points studied here and (ii) a probably much greater role for Na + in facilitating fluid movement across duct cells than we had previously hypothesized. 13, 14 Additional physiological and molecular studies 26, 27 are needed to understand the specific mechanism(s) involved in fluid secretion from the transduced duct cells.
The protein composition of saliva showed more modest changes, both in total values, as well as specifically for amylase ( Table 1) . The amylase values reported by us previously 16 weeks after IR and 3 days following AdhAQP1 administration were similar to those observed herein (total protein was not studied previously). 14 In addition, we did not see any consistent, significant effect of hAQP1 gene transfer on parotid salivary protein composition, when analyzed by SDS gel electrophoresis and silver staining, 8 weeks after administration (see Supplementary Figure 2) .
The findings in the present study are important for the continued development of a long-term gene therapy approach for the treatment Representative results of western blot analyses are shown. 10 mg of crude membrane protein was subjected to SDS-gel electrophoresis and western blotting, as described in Materials and Methods. Lane 1, positive control membranes from rat kidney; lane 2, membranes from an AAV2hAQP1-transduced, irradiated minipig parotid gland (8 weeks after 1Â10 11 vp was delivered) showing AQP1 expression; lane 3, membranes from an AAV2LacZ-transduced, irradiated minipig parotid gland (8 weeks after 1Â10 11 vp was delivered) showing little AQP1 expression; lane 4, membranes from saline-infused, irradiated minipig parotid gland, also showing little AQP1expression; lane 5, membranes from the non-irradiated, contralateral side, showing AQP1 expression normally present in minipig parotid glands, which is derived from microvascular endothelial cells. 8, 14, 23 The migration position of all immunopositive protein bands represents the non-glycosylated AQP1 monomer (28 kDa). 28 Although AAV2-mediated transgene expression in minipig parotid glands is transient, AAV2 transduction of rhesus macaque parotid glands is significantly more stable (up to 6 months following peak expression levels; length of experiment 19 ). Nonetheless, in the event human parotid glands exhibit similar AAV2-mediated expression patterns as those observed in minipigs, the delivery of alternative AAV serotypes likely can be used to extend transgene expression. 29 In conclusion, the studies presented herein support the hypothesis that the AAV2hAQP1 vector would be useful for targeting IR-surviving duct cells in previously irradiated head and neck cancer patients, and provide them with a more extended (months) means of increasing salivary flow versus the AdhAQP1 vector (days).
MATERIALS AND METHODS Animals
Healthy male minipigs (total studied, n¼20), B8 months old, weighing 25-30 kg were obtained from the Institute of Animal Science of the Chinese Agriculture University. Animals were kept under conventional conditions with free access to water and food. Food stock (200-250 g, mixed with water) was provided twice daily, at 0830 and 1700 hours. This study was reviewed and approved by the Animal Care and Use Committee of Capital Medical University.
IR of parotid glands
All minipigs were subjected to a single IR dose of 20 Gy directed at one parotid gland using a three-dimensional conformal technique. 14, 21 Three separate cohorts of animals were studied, using the same general experimental design. Animals were first anesthetized with a combination of ketamine chloride (6 mg kg À1 ) and xylazine (0.6 mg kg À1 ) injected intramuscularly. A radiation field of 12Â10 cm 2 , and a 95 cm source-to-skin distance, including one parotid gland, was defined using an X-ray simulator for each minipig and the margins tattooed on the skin for the subsequent exposures. Thereafter, animals were placed on their side and 20 Gy was directed to the targeted parotid gland (randomly selected right or left glands) using a Philips linear accelerator (SL 7520 Philips Medical Systems, Inc., Bothell, WA, USA) with 6 mV of photon energy at 3.2 Gy min À1 . The contralateral gland was outside of the radiation field and received o1 Gy.
AAV2 vector preparation and administration
Generation of AAV2 vectors was performed under helper-free conditions using established methods, as previously described. 17, 22 The cytomegalovirus promoter was used to drive transgene expression. Crude viral lysates obtained after three freeze-thaw cycles from co-transfected 293T cells were treated with benzonase (100 units ml À1 crude viral lysate; 37 1C for 45 min), adjusted to a refractive index of 1.372 by addition of CsCl and centrifuged (SW41 rotor) at 38 000 r.p.m. for 65 h at 20 1C. Equilibrium density gradients were fractionated, fractions with a refractive index of 1.369-1.375 were collected, and vector presence was determined by quantitative PCR. After pooling appropriate fractions, vector titers were determined by quantitative PCR. The sequences used for the forward primer, reverse primer and probe were selected using Primer Express Primer Design software (PE Applied Biosystems, Foster City, CA, USA) on the basis of the cytomegalovirus promoter. Vector titers were B10 12 vp ml À1 . Viral fractions were dialyzed against 0.9% NaCl immediately before experiments.
Gene transfer procedures were performed as described. 22, 30 In brief, minipigs were fasted (that is, water available, but solid food withheld) for 12 h before performing the gene transfer. Animals were anesthetized, as above, placed on their side and polyethylene tubing (Intramedic, PE10, Becton-Dickinson, Sparks, MD, USA) used to cannulate the anterior part of the parotid (Stensen's) duct. Atropine (0.02 mg kg À1 ) was injected intramuscularly 30 min before cannulation. Cannulae were inserted approximately 3 cm into the orifice of the duct. Vectors were suspended in 0.9% NaCl, pH 7.4 and delivered to the targeted parotid glands by retrograde infusion. Glands received from 10 10 to 3Â10 11 vp (see Figure legends for Figures 2 and 3 , and related text, for details) in an infusion volume of 4 ml.
Histological and immunocytochemical analyses
Following sacrifice, parotid glands were obtained from animals. Tissues were quickly removed, cleaned of extraneous tissue, cut into multiple pieces (B5Â5Â5 mm), fixed in 10% formalin, embedded in paraffin and then sectioned at 3-4 mm. The sections were either (i) stained with hematoxylin and eosin, and examined for evidence of pathological changes (there were none observed) or (ii) processed for evidence of AQP1 expression exactly as described previously. 14 
Collection of blood and saliva
Parotid saliva was collected, and salivary flow rates determined, using a modified Carlson-Cittenden cup 14 on anesthetized animals following an intramuscular injection of pilocarpine (0.1 mg kg À1 ). The collection device was identical to that used clinically in collecting parotid saliva from children and adolescents (9 mm inner ring diameter; 16 mm outer ring diameter). Parotid saliva was collected from each parotid gland of all animals for B10 min on the days indicated in the Results and Discussion section and Figures. Blood was obtained from the precaval vein at the same time points.
Western blot analyses
Western blots for hAQP1 expression were performed as previously described. 14 In brief, frozen tissue samples were thawed on wet ice, placed in ice-cold homogenization buffer (TE buffer, 10 mM Tris-HCl, pH 7.4), minced with scissors and homogenized in a Polytron homogenizer (twice, in 10 s bursts at setting 5). After centrifugation at 1000 g for 10 min, supernatants were collected and re-centrifuged at 17 000 g for 30 min. The resulting supernatant was discarded and the final pellet re-suspended in 20 ml loading buffer. A protein assay was performed and 10 mg of protein was loaded per lane for gel electrophoresis and western blotting. Samples were electrophoresed in 12% SDS polyacrylamide gels, and incubated with anti-sera directed at the C-terminus of hAQP1, as previously reported. 14 
Clinical laboratory analyses with blood and saliva samples
As previously reported, 14 collected saliva and blood samples were analyzed by standard clinical chemistry and, for blood, hematology procedures. Serum analyses performed included Na + , K + , Cl À , Ca 2+ , phosphorous, glucose, total protein, albumin, globulin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, blood urea nitrogen, alkaline phosphatase, amylase and creatinine. Hematology analyses included the number of white blood cells, red blood cells, platelets, hematocrit, concentration of hemoglobin, mean corpuscular volume, % lymphocytes, % monocytes and % granulocytes. Parotid saliva samples were analyzed for total protein, albumin, amylase, Na + , K + , Cl À , Ca 2+ and PO 4 À . Data at different time points were analyzed using a one-way analysis of variance followed by the Tukey test, and representative results are shown in Table 1 Figure 2) , 10 ml of each parotid saliva sample was electrophoresed in 12% SDS polyacrylamide gels, as described above, and silver stained as reported. 31 
Assessment of AAV2 serum neutralizing antibodies
To determine whether neutralizing antibodies to AAV2 were present in serum, we evaluated all serum samples using an assay similar to one previously AAV2hAQP1 and radiation-induced xerostomia R Gao et al described by Katano et al. 32 Titers are reported as that dilution of serum that resulted in a 50% inhibition in measuring transduction of 293 cells with an AAV2 vector expressing green fluorescence protein.
Assessment of serum and salivary cytokine levels
Serum and saliva samples were examined by enzyme-linked immunoabsorbance assays (all from R&D Systems; Minneapolis, MN, USA) for the presence of several cytokines: granulocyte macrophage colony-stimulating factor, interleukin-2, interleukin-6, interferon g and macrophage inhibitory protein-1b. Before measuring actual experimental samples, randomly chosen serum and saliva samples were tested for enzyme-linked immunoabsorbance assay interference using spiking assays with standard proteins obtained with the enzymelinked immunoabsorbance assay kits. None of the samples showed evidence for assay inhibition or enhancement. All samples used for final data determination were assayed in duplicate.
